An interventional study of Biofreedom and Orsiro in Ischaemic Heart Disease, sponsored by Odense University Hospital. Completed at 1 site in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Odense University Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Coronary Artery Disease by Odense University Hospital — 1 open to participants now, 2 under way, none of them phase 3. Coronary Artery Disease · Odense University Hospital.
Among the 14 studies in Coronary Artery Disease by Odense University Hospital, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2015, is one of 10 with no phase, and was the 7th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →1 of the 14 studies in Coronary Artery Disease by Odense University Hospital is open now, in 1 country. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
Ages 18+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3,150 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 104 across the 11 interventional studies, 314 across the 3 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Odense University Hospital is the lead sponsor of 480 studies on the registry; 111 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Coronary Artery Disease by Odense University Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the Danish Organization for Randomized Trials with Clinical Outcome (SORT OUT) is to compare the safety and efficacy of the polymer-free Biolimus-eluting BIOFREEDOM stent with a biodegradable-polymer Sirolimus-eluting ORSIRO stent in a population-based setting, using registry detection of clinically driven events
SORT OUT IX is a randomized, multicenter, all-comer, two-arm, non-inferiority trial comparing the polymer-free Biolimus-eluting BIOFREEDOM stent with a biodegradable-polymer Sirolimus-eluting ORSIRO stent in treating atherosclerotic coronary artery lesions.
Patients will be enrolled by the investigators and randomly allocated to treatment groups after diagnostic coronary angiography and before percutaneous coronary intervention. Block randomization by centre (permuted blocks of random sizes (2/4/6)) will be used to assign patients in a 1:1 ratio to receive the polymer-free Biolimus-eluting BIOFREEDOM stent (Biosensors) or the biodegradable-polymer Sirolimus-eluting ORSIRO stent (Biotronik). A web based Trial Partner randomization system will be used.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biofreedom stent treatment at index procedure
Device: Biofreedom
Orsiro stent treatment at index procedure
Device: Orsiro
PCI with Biofreedom stent
PCI with Orsiro stent
Target Lesion Failure
Primary endpoint assessed after 12 months
Time frame: 12 months
Target lesion failure
Target lesion failure will be assessed yearly up to 5 years after index procedure
Time frame: 2 year, 3 year, 4 year, 5 year
Stent thrombosis
Stent thrombosis will be assessed yearly up to 5 years after index procedure
Time frame: 1 year, 2 years, 3 years, 4 years, 5 years
Myocardial infarction
Myocardial infarction will be assessed yearly up to 5 years after index procedure
Time frame: 1 year, 2 years, 3 years, 4 years, 5 years
Cardiac death
Cardiac death will be assessed yearly up to 5 years after index procedure
Time frame: 1 year, 2 years, 3 years, 4 years, 5 years
All cause mortality
All cause mortality will be assessed yearly up to 5 years after index procedure
Time frame: 1 year, 2 years, 3 years, 4 years, 5 years
Target lesion revascularization
Target lesion revascularization will be assessed yearly up to 5 years after index procedure
Time frame: 1 year, 2 years, 3 years, 4 years, 5 years
Target vessel revascularization
Target vessel revascularization will be assessed yearly up to 5 years after
Time frame: 1 year, 2 years, 3 years, 4 years, 5 years
The record gives a start of Dec 2015, a primary completion of Oct 2018 and a completion of Oct 2023. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.